Abdominal paracentesis to overcome clinical worsening in severe pulmonary arterial hypertension (PAH) patients: first experience in three patients on combination therapy including Treprostinil

被引：0
|
作者：
Steringer-Mascherbauer, R.
Sailer, T.
Ebner, C.
Fuegger, R.
Marecek, I.
Wittrich, S.
Lummerstorfer, M.
Nesser, H. J.
机构：
[1] Krankenhaus Elisabethinen, Interne Kardiol Angiol Intens Med 2, Linz, Austria
[2] AOP Orphan, Vienna, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2013年 / 125卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IX-3
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [1] Abdominal Paracentesis To Overcome Clinical Worsening In Severe Pulmonary Arterial Hypertension (pah) Patients: First Experience In Three Patients On Combination Therapy Including Treprostinil
    Steringer-Mascherbauer, R.
    Sailer, T.
    Marecek, I.
    Nesser, H.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [2] One year experience with intravenous treprostinil in pulmonary arterial hypertension (PAH) patients
    McLaughlin, VV
    Barst, R
    Gomberg-Maitland, M
    Tapson, V
    Krichman, A
    Widlitz, A
    Rich, S
    Benza, R
    [J]. CHEST, 2005, 128 (04) : 160S - 160S
  • [3] Sitaxsentan improves time to clinical worsening in patients with pulmonary arterial hypertension (PAH).
    Badesch, D
    Galie, N
    Langleben, D
    Naeije, R
    Simonneau, G
    Barst, RJ
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S167 - S167
  • [4] Sitaxsentan improves time to clinical worsening (TCW) in patients with pulmonary arterial hypertension (PAH)
    Oudiz, R. J.
    Frost, A. E.
    Lawrence, E. C.
    Galie, N.
    Barst, R. J.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2006, 25 (02): : S75 - S75
  • [5] Sitaxsentan improves time to clinical worsening (TCW) in patients with pulmonary arterial hypertension (PAH)
    Oudiz, RJ
    Frost, AE
    Lawrence, EC
    Galie, N
    Barst, RJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 307A - 307A
  • [6] Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension
    D'Alto, M.
    Romeo, E.
    Argiento, P.
    Badagliacca, R.
    Papa, S.
    Farro, A.
    Sarubbi, B.
    Russo, M. G.
    Vizza, C. D.
    Golino, P.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 3037 - 3037
  • [7] Triple Combination Therapy Including Inhaled Treprostinil in High Risk Patients with Pulmonary Arterial Hypertension Unsuited for Infused Prostanoid Therapy
    Swisher, J.
    Overton-Barnes, R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [8] Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients
    Hamilton, Neil
    Sellars, Michaela
    Graves, Mark
    Armstrong, Iain
    Charalampopolous, Athanasios
    Kiely, David
    Elliot, Charlie
    Condliffe, Robin
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [9] Effects Of SC Treprostinil On Top Of Double Oral Combination Therapy In Patients With Pulmonary Arterial Hypertensione (PAH) And Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
    Leci, E.
    Palazzini, M.
    Beciani, E.
    Conficoni, E.
    Sgro, F.
    Sciarra, F.
    Bachetti, C.
    Manes, A.
    Galie, N.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [10] Commentary on Symptom Experience of Pulmonary Arterial Hypertension (PAH) Patients
    Khan, Ehsan Ullah
    [J]. CLINICAL NURSING RESEARCH, 2011, 20 (02) : 135 - 143
12345